WASHINGTON, July 6, 2026 — The U.S. Food and Drug Administration (FDA) has approved allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq (Orca-T®; Tregzi™), a new approach to stem cell transplants for blood cancer patients.
Unlike standard approaches, Orca-T is engineered for each individual patient using cells from a matched donor, combining key parts of the immune system in a way that aims to both protect against cancer and reduce harmful side effects.
“Historically, a stem cell transplant, which is sometimes the only curative option for blood cancer, has often meant navigating serious, long-term effects that can shape patients’ lives well beyond treatment,” said Gwen Nichols, M.D., executive vice president and chief medical officer at Blood Cancer United. “As a researcher, physician and a patient advocate, it’s exciting that patients will have a new option that may to support recovery and improve quality of life.”
Treatment with Orca-T led to improved outcomes compared with a standard transplant approach in a clinical trial of 187 patients including those with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, who underwent a matched-donor stem cell transplant.
Seventy-eight percent of patients who received the investigational treatment were alive without chronic graft-versus-host disease (GvHD), compared with 38% of those who received a conventional transplant.
Learn more about navigating cancer care and what side effects cGvHD may cause
Patients who were treated with the investigational treatment also had fewer bouts of chronic GVHD, fewer serious infections, and a reduced risk of death unrelated to their cancer returning.
If you or a loved one need personalized disease, treatment or support information, you can contact one of our Information Specialists here.